前立腺癌患者における血中I型プロコラーゲンC末端プロペプチド(P1CP)およびI型コラーゲンC末端テロペプチド(1CTP)の測定と臨床的有用性について

Abstract

前立腺癌骨転移症例におけるP1CP, 1CTPの意義について検討した. 1)その感度, 特異度からすると初回の骨転移検出に関しては画像診断の補助的手段にすぎないと思われた. 2)血清値上昇例については骨転移巣の治療効果を追跡する上で骨シンチグラムを代替できる可能性がある. 3)骨に主たる評価可能病変を有し, 前立腺特異抗原低値症例では病勢の判定や予後の推定に有用と思われた

Carboxyterminal propeptide of type I collagen (P1CP) and cross-linked carboxyterminal telopeptide of type I collagen (1CTP) are known as parameters of bone metastasis in patients with prostate cancer (PCa). We measured the serum P1CP and 1CTP levels in 52 PCa patients and evaluated the clinical usefulness of these serum markers. Both serum levels of P1CP and 1CTP were significantly higher in patients with extent of disease (EOD) grade 2 or 3 bone metastases than in patients without bone metastasis. Thus, P1CP and 1CTP are not as useful at first detection of bone metastases as bone scintigram. On the other hand, in the patients who indicated high serum levels of P1CP or 1CTP before initial treatment, the changes in the concentrations of these markers may be helpful in evaluating the response to treatment or the progression of disease. Our results suggest that P1CP and 1CTP are useful markers for monitoring the metastatic burden in the bone of PCa patients, but the efficacy is limited in high EOD grade cases.